CLINICAL EVALUATION OF A NEW ORAL CEPHEM, CEFPODOXIME PROXETIL, IN CHILDREN

Cefpodoxime proxetil (CPDX-PR, CS-807) was evaluated for its efficacy, safety and pharmacokinetics in children. CPDX-PR was effective in 93.6% of 47 cases with respiratory tract, middle ear, skin or urinary tract infections. Twice or 3 times daily administration of 3mg/kg each was sufficient to trea...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1989/07/25, Vol.42(7), pp.1561-1570
Main Authors: MEGURO, HIDENORI, ARIMASU, OSAMU, SHIRAISHI, HIROAKI, TAJIMA, TAKESHI, HIRUMA, FUJIAKI, NISHIMURA, SHUICHI, SUGIE, NOBUYUKI, SUGAMATA, KUMIKO, ABE, TOSHIAKI, FUJII, RYOCHI, KAKUTA, OSAMU, FUKUYAMA, TAMIKO
Format: Article
Language:Japanese
Subjects:
Administration, Oral
Bacterial Infections - drug therapy
Bacterial Infections - metabolism
Bacterial Infections - microbiology
Cefpodoxime Proxetil
Ceftizoxime - administration & dosage
Ceftizoxime - analogs & derivatives
Ceftizoxime - pharmacokinetics
Ceftizoxime - therapeutic use
Chemical Phenomena
Chemistry
Child
Child, Preschool
Drug Evaluation
Female
Half-Life
Humans
Infant
Male
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - metabolism
Respiratory Tract Infections - microbiology
Urinary Tract Infections - drug therapy
Urinary Tract Infections - metabolism
Urinary Tract Infections - microbiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cefpodoxime proxetil (CPDX-PR, CS-807) was evaluated for its efficacy, safety and pharmacokinetics in children. CPDX-PR was effective in 93.6% of 47 cases with respiratory tract, middle ear, skin or urinary tract infections. Twice or 3 times daily administration of 3mg/kg each was sufficient to treat streptococcal pharyngitis and Haemophilus influenzae infections. No severe adverse reaction was encountered in 52 cases treated with CPDX-PR. The serum half-life was approximately 2.17±0.24 hours after oral administration.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.42.1561